Uremia increases QRS duration after β-adrenergic stimulation in mice

Morten B Thomsen1, Morten S Nielsen1, Annemarie Aarup1

  • 1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Physiological Reports
|July 10, 2018
PubMed

Insights

Chronic kidney disease (CKD) disrupts the normal diurnal rhythm of heart electrical activity, specifically QRS duration. This study in mice reveals altered sympathetic regulation of cardiac function in CKD, contributing to sudden cardiac death risk.

Area of Science:

  • Cardiology
  • Nephrology
  • Electrophysiology

Background:

  • Chronic kidney disease (CKD) and uremia are linked to increased risks of heart disease and sudden cardiac death.
  • While coronary artery disease is a known factor, other mechanisms, potentially involving cardiac arrhythmias, remain unclear.

Purpose of the Study:

  • To investigate the electrophysiological changes in mice with mild CKD to identify potential causes of sudden cardiac death.
  • To determine if CKD affects cardiac electrical activity and its regulation by the sympathetic nervous system.

Main Methods:

  • Mild CKD was induced in mice via partial (5/6) nephrectomy (NX).
  • Electrophysiological studies, including ECG in conscious mice and intracardiac pacing in anesthetized mice, were performed.
  • Echocardiography and ex vivo measurements of cardiac conduction velocity were also conducted.

Main Results:

  • NX mice exhibited a loss of the normal 24-hour diurnal rhythm in QRS duration compared to controls.
  • Beta-adrenergic stimulation (isoprenaline) prolonged QRS duration in NX mice but not in controls.
  • No spontaneous arrhythmias were observed, and arrhythmia vulnerability was comparable between NX and control mice.

Conclusions:

  • Proper kidney function is essential for maintaining the diurnal variation of QRS duration.
  • Sympathetic nervous system regulation of cardiac QRS duration is altered in the context of kidney disease.
  • These findings suggest a potential role for altered cardiac electrophysiology in the increased sudden cardiac death risk associated with CKD.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.9K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.5K
Increasing Function01:18

Increasing Function

An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
397